Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppressive agents. There is no data on the impact of r...

Full description

Bibliographic Details
Main Authors: David Liu, F Stephen Hodi, Rizwan Haq, Anita Giobbie-Hurder, Ann W Silk, Patrick A Ott, Tamara A Sussman, Elizabeth I Buchbinder, Anna K Maloney, Nikita Katukota, Miklos C Fogarasi, Megan Insco
Format: Article
Language:English
Published: BMJ Publishing Group 2024-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/8/e009061.full

Internet

https://jitc.bmj.com/content/12/8/e009061.full

Similar Items